Skip to main content
. 2020 Sep 30;21(19):7252. doi: 10.3390/ijms21197252

Figure 5.

Figure 5

GFAP immunoreactivity in transplanted RCS rats. Microphotographs of representative retinal cross-sections taken from the control Pievald Viro Glaxo (PVG) rats (A), and the right untreated eyes (B) and left treated eyes (C–J) of RCS rats that received IVI (C–F) or SRI (G–J) of hBM-MSCs. Immunostaining for GFAP (red; goat anti-GFAP antibody), CD45 (transplanted cells; green; mouse anti-human CD45 antibody) and DAPI counterstaining (blue) of the retinas can be observed at different time periods after the injection. Graphs show the mean relative fluorescence units ± SD of GFAP immunofluorescence in the retinas of control PVG rats (black bars; include data from both right and left eyes) and in the right uninjected eyes (blue bars) and left eyes (red bars) of RCS rats that received an IVI (K) or SRI (L) of hBM-MSCs. GFAP immunoreactivity was significantly higher in the right (uninjected) eyes at all the survival periods. * p < 0.005, # p < 0.005 compared to previous survival interval. n = 6 eyes for control group and treated eyes group at all time points studied; n = 12 eyes for untreated eyes group at all time points studied. Scale bar: 100 μm.